Summit Therapeutics Inc. — Form 8-K
Filed November 4, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
AstraZeneca completed a $2.0 billion strategic equity investment in Summit on October 5, 2026, purchasing ~108,955 shares of preferred stock convertible at a 1:1,000 ratio (implying $18.36 per common share). The investment fuels ivonescimab development across multiple indications. Clinically, ivonescimab met PFS but missed OS significance in the HARMONi Phase III NSCLC trial (FDA BLA pending, PDUFA date November 14, 2026); however, Akeso-sponsored HARMONi-2 and HARMONi-GI1 trials showed statistically significant OS benefits in NSCLC and biliary tract cancer. Q3 2026 cash position was $629.8M (post-investment: $2.63B); non-GAAP R&D expenses rose 60% YoY to $145.2M due to expanded clinical programs.
Why this rating
AstraZeneca $2B investment is ~80% of company market cap, providing major runway and validation; offset by failed OS endpoint in lead HARMONi trial, creating regulatory and commercial uncertainty on November 14 FDA decision.
Price action (we called it positive)
before filing · preread $15.50 | at our read pending | +10 min pending | +30 min pending | +1 hr pending | +4 hrs pending |
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from November 4, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.